Literature DB >> 18775609

Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.

Marc L'hermite1, Tommaso Simoncini, Sarah Fuller, Andrea Riccardo Genazzani.   

Abstract

Hormone replacement therapy (HRT) in young postmenopausal women is a safe and effective tool to counteract climacteric symptoms and to prevent long-term degenerative diseases, such as osteoporotic fractures, cardiovascular disease, diabetes mellitus and possibly cognitive impairment. The different types of HRT offer to many extent comparable efficacies on symptoms control; however, the expert selection of specific compounds, doses or routes of administration can provide significant clinical advantages. This paper reviews the role of the non-oral route of administration of sex steroids in the clinical management of postmenopausal women. Non-orally administered estrogens, minimizing the hepatic induction of clotting factors and others proteins associated with the first-pass effect, are associated with potential advantages on the cardiovascular system. In particular, the risk of developing deep vein thrombosis or pulmonary thromboembolism is negligible in comparison to that associated with oral estrogens. In addition, recent indications suggest potential advantages for blood pressure control with non-oral estrogens. To the same extent, a growing literature suggests that the progestins used in association with estrogens may not be equivalent. Recent evidence indeed shows that natural progesterone displays a favorable action on the vessels and on the brain, while this might not be true for some synthetic progestins. Compelling indications also exist that differences might also be present for the risk of developing breast cancer, with recent trials indicating that the association of natural progesterone with estrogens confers less or even no risk of breast cancer as opposed to the use of other synthetic progestins. In conclusion, while all types of hormone replacement therapies are safe and effective and confer significant benefits in the long-term when initiated in young postmenopausal women, in specific clinical settings the choice of the transdermal route of administration of estrogens and the use of natural progesterone might offer significant benefits and added safety.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18775609     DOI: 10.1016/j.maturitas.2008.07.007

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  20 in total

Review 1.  Estrogen neuroprotection and the critical period hypothesis.

Authors:  Erin Scott; Quan-guang Zhang; Ruimin Wang; Ratna Vadlamudi; Darrell Brann
Journal:  Front Neuroendocrinol       Date:  2011-11-04       Impact factor: 8.606

Review 2.  Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease.

Authors:  Durr-e-Nayab Masood; Emir C Roach; Katie G Beauregard; Raouf A Khalil
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

3.  Postmenopausal estrogen therapy: which route to take?

Authors:  James A Simon
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-03

Review 4.  State of the evidence 2017: an update on the connection between breast cancer and the environment.

Authors:  Janet M Gray; Sharima Rasanayagam; Connie Engel; Jeanne Rizzo
Journal:  Environ Health       Date:  2017-09-02       Impact factor: 5.984

Review 5.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

Review 6.  Bioidentical hormone therapy.

Authors:  Julia A Files; Marcia G Ko; Sandhya Pruthi
Journal:  Mayo Clin Proc       Date:  2011-04-29       Impact factor: 7.616

Review 7.  Estrogen therapy and cognition: a review of the cholinergic hypothesis.

Authors:  Robert B Gibbs
Journal:  Endocr Rev       Date:  2009-12-17       Impact factor: 19.871

8.  Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study.

Authors:  J Ryan; I Carrière; J Scali; J F Dartigues; C Tzourio; M Poncet; K Ritchie; M L Ancelin
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

Review 9.  Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2016-08-08       Impact factor: 4.507

10.  Association of progesterone receptor gene (PGR) variants and breast cancer risk in African American women.

Authors:  Courtney A Gabriel; Nandita Mitra; Angela Demichele; Timothy Rebbeck
Journal:  Breast Cancer Res Treat       Date:  2013-06-14       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.